Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Breast
• Colon
• Head and Neck
• Hematology
• Hepatic
• Leukemia
• Lung
• Lymphoma
• Melanoma
• Myelomas
• Prostate
• Solid Tumors
• Cholangiocarcinoma

 

Breast

• Elacestrant vs. SOC in patients with ER+/HER- early breast cancer

  Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
  

  ---

• Study of MK-2870 as a single agent and + Pembrolizumab vs Physician’s choice in patients with HR+/HER- breast cancer

  An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  

  ---

• Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I

  Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)
  

  ---

• Dato-DXd w/or w/o Durvalumab vs. Investigator’s choice in patients with PDL1+ Triple Negative Breast Cancer

  A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
  

  ---

• Dato-DXd + Durvalumab vs Pembrolizumab + Chemo in patients with neo-adjuvant Triple negative breast cancer

  A Phase III, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Cheomotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
  

  ---

• Zanidatamab + physician’s choice chemo vs. trastzumab + physician’s choice chemo for stage IV HER2+ breast cancer

  A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment (JZP598-303)
  

  ---

• Tucatinib in Combination w/Doxil for HER2+ metastatic breast ca

  Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)
  

  ---

• DB-1303 vs. SOC in HER2low, HER+ Metastatic breast cancer

  A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy
  

  ---

• Adjuvant Sacituzumab Govitecan & Pembrolizumab vs. SOC tx in patients with TNBC

  A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
  

  ---

• Camizestrant vs. Endorine Therapy as Adjuvant Treatment in Early Breast cancer

  A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
  

  ---

• Phase 3 Study of Adjuvant Endocrine Therapy vs. Imlunestrant

  A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
  

  ---

• Phase III Study Comparing Gedatolisib + Palbociclib & Fulvestrant to SOC treatments in Breast Ca

  A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
  

  ---

Colon

• A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

  A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
  

  ---

• MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors

  Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)
  

  ---

• Phase 3 study of MRTX849 + Cetuximab vs. Chemo in patients with colon cancer w/KRAS G12C mutation

  A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
  

  ---

Head and Neck

• Dostarlimab after Chemoradiation in pts w/locally advanced unresected H&N carcinoma

  A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
  

  ---

• Petosemtamab + Pembrolizumab vs. Pembrolizumab in 1st line treatment of PD-L1+ Head & Neck squamous cell carcinoma

  A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
  

  ---

• Petosemtamab + investigator’s choice in patients w/previously treated Stage IV HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  ---

• Pembrolizumab +/- Zanzalintinib in 1st line tx of PD-L1+ Head and Neck cancer

  A Phase 2/3, randomized, double-blind, controlled study of Zanzalintinib (XL092) in combination with pembrolizumab vs pembrolizumab in the first-line treatment of subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma
  

  ---

Hematology

• Luspatercept vs. Epoetin Alfa for the treatment of Anemia due to Low-Risk MDS

  A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial
  

  ---

Hepatic

• A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

  A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
  

  ---

Leukemia

• BL M11D1 in patients with Relapsed/Refractory Acute Myeloid Leukemia

  A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (BL-M11D1-HM-101)
  

  ---

Lung

• Study of Ivonescimab vs. Pembrolizumab for First line Treatment of NSCLC

  A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
  

  ---

• Study of BMS-986489 vs durvalumab in limited stage small cell lung cancer

  An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)
  

  ---

• BMS-986489 + Carboplatin + Etoposide vs. Atezolizumab + Carboplatin + Etoposide in small cell lung cancer

  A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
  

  ---

• ABP234 and Keytruda in subjects with Stage IV NSCLC

  A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (20210033)
  

  ---

• EIK1001 + Pembrolizumab and Chemotherapy in Patients with Metastatic NSCLC

  A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)
  

  ---

• GDC-6036 in combination w/other anti-cancer therapies in untreated metastatic NSCLC w/KRAS G12C mut

  A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation
  

  ---

• A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

  A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer
  

  ---

• SGN-B6A compared with docetaxel in previously treated NSCLC

  A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer
  

  ---

• Avutometinib + Sotorasib in Patients with KRAS G12C mutant NSCLC

  A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
  

  ---

• Multiple Therapies according to biomarker status in patients with Lung Cancer

  A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with locally advanced, unresectable, Stage III Non-Small Cell Lung Cancer
  

  ---

• Screening Study to determine biomarker status for patients with malignant tumors

  Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors
  

  ---

Lymphoma

• Zilovertamab Vedotin + R-CHP in untreated DLBCL

  A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010)
  

  ---

• Epcoritamab + Rituximab and Lenalidomide vs. Chemoimmunotherapy in Previously Untreated Follicular Lymphoma

  A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma
  

  ---

• Stage 3 study of Tazemetostat/placebo + Lenalidomide and Rituximab in Patients with FL

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)
  

  ---

Melanoma

• Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

  A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.
  

  ---

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

Myelomas

• Mezigdomide, Bortezomib and Dexamethasone vs. Pomalidomide, Bortezomib and Dexamethasone in relapsed/refractory MM

  A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM):Successor-1 (CA057-001)
  

  ---

• Iberdomide, Daratumumab, and Dexamethasone vs. Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory MM

  A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)
  

  ---

• Mezigdomide, Carfilzomib, and Dexamethasone vs. Carfilzomib and Dexamethasone in relapsed/refractory MM

  A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2 (CA057008)
  

  ---

• Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

  Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)
  

  ---

Prostate

• Ifinatamab Deruxtecan vs. Docetaxel for Metastatic Castration-Resistant Prostate Cancer

  A Phase 3, Open-label study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Ideate-Prostate01)
  

  ---

• 177Lu vipivotide tetraxtan vs. Observation in PSMA positive metastatic prostate patients

  An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (CAAA617D12302)
  

  ---

• MK-5684 vs Abiraterone or Enzalutamide in patients with mCRPC who have progressed on 1 prior NHA

  A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  

  ---

• MK-5684 vs. Abiraterone or Enzalutamide in pts w/mCRPC

  A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
  

  ---

Solid Tumors

• Zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (

  A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)
  

  ---

• MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors

  Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)
  

  ---

Cholangiocarcinoma

• Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

  Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  ---